

DAFTAR PUSTAKA

- Abu-Amero KK, Kondkar AA, Chalam KV. Resveratrol and Ophthalmic Diseases. *Nutrients*. 2018; 8:200.
- Ahmed Z, Kalinski H, Berry M, et al. Ocular neuroprotection by siRNA targeting caspase-2. *Cell Death Dis*. 2011;2:173.
- Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. *Oncogene* 2003;22(53):8581-9.
- Babu SR, Bao F, Roberts CM, et al. Caspase 7 is a positional candidate gene for IDDM 17 in a Bedouin Arab family. *Ann NY Acad Sci* 2003;1005:340–3.
- Baig MN, Lubow M, Immesoete P, et al. Vision loss after spine surgery: review of the literature and recommendations. *Neurosurgical focus*. 2007;23(5).
- Berson DM, Dunn FA, Takao M. Phototransduction by retinal ganglion cell that set the circadian clock. *Science*.2002;295(5557): 1070-3.
- Boatright KM, Salvesen GS. Mechanisms of caspase activation. *Current opinion in cell biology*. 2003;15:725-731.
- Chaon BC, Lee MS. Is there treatment for traumatic optic neuropathy?. *Curr Opin Ophthalmol*. 2015;26:445-9.
- Cheung ZH, Chan Y-M, Siu FKW, et al. Regulation of caspase activation in axotomized retinal ganglion cells. *Mol Cell Neurosci*. 2004;25:383–93.
- Chou PI, Sadun AA, Chen YC, Su WY, Lin SZ, Lee CC. Clinical experiences in the management of traumatic optic neuropathy. *Neuro-ophthalmology*.1996;18:325–336.

Choudhury S, Liu Y, Clark AF, et al. Caspase-7: A Critical Mediator of Optic Nerve Injury-Induced Retinal Ganglion Cell Death. Molecular Neuroregeneration. 2015; 10:40.

Cook MW, Levin LA, Joseph MP, Pinczower EF. Traumatic optic neuropathy. A meta-analysis. Arch Otolaryngol Head Neck Surg. 1996;122:389–392.

Corredor RG, Goldberg JL. Retinal Ganglion Cell Life and Death Mechanism and Implications for Ophthalmology. Touch Briefing. 2009;109-112.

Cucciolla V, Borriello A, Olivia A, et al. Resveratrol: From Basic Science to the Clinic. Cell Cycle. 2007; 6:2495-2510.

Denault JB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem Rev. 2002;102:4489-99.

Ding Z, Cao J, Shen Y, et al. Resveratrol promotes nerve regeneration via activation on p300 acetyltransferase-mediated VEGF signalling in a rat model of sciatic nerve crush injury. Front Neurosci. 2018;12:341.

Doganay S, Firat PG, Cankaya C, et al. Evaluation of the effects of resveratrol and bevacizumab on experimental corneal alkali burn. Burns 2013; 3:, 326–30.

Doganay S, Borazan M, Iraz M, et al. The Effect of Resveratrol in Experimental Cataract Model formed by Sodium Selenite. Curr eye Res. 2006; 31: 147-153.

Entezari M, Esmaeili M, Yaseri M. A pilot study of the effect of intravenous & erythropoietin on improvement of visual function in patients with recent indirect traumatic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2014;252:1309 – 1313.

Fonseca-Kelly Z, Nassrallah M, Uribe J, Khan RS, Dine K, Dutt M, Shindler KS. Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis. Frontiers in neurology, 2012;6(84):1-9.

Fulda S, Debatin KM. Resveratrol modulation of signal transduction in apoptosis and cell survival: A mini-review. *Cancer Detection and Prevention*. 2006; 30: 217–223.

Gafni J, Cong X, Chen SF, et al. Calpain-1 Cleaves and Activates Caspase-7. *J Biol Chem*. 2009; 283 (37): 25441-9.

Goldberg JL. Optic Nerve in Adler's Physiology of The Eye. Elsevier. 2011; 550-567.

Goldenberg-Cohen N, Miller NR, Repka MX. Traumatic optic neuropathy in children and adolescent. *J AAPOS* 2004;8(1):20-27.

Haerweth RS, Quigly HA. Visual field defects and retinal ganglion cell losses in patients with glaucoma. *Arch ophthalmol*. 2006; 126(6): 835-859.

Harris JN, Miller NR. Traumatic Optic Neuropathy. In *Emergencies of The Orbit and Adnexa*. Springer. 2017; 113-137.

Hashimoto T, Kikkawa U, Kamada, S. Contribution of Caspase(s) to the Cell Cycle Regulation at Mitotic Phase. *Plos ONE* 6(3), 2011;1-9.

Hermel E, Gafni J, Propp SS, et al. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. *Cell Death Differ* 2004;11:424–38.

Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. *Nat Rev Immunol* 2006;6:813–22.

Hughes B. Indirect injury of the optic nerve and chiasm. *Bull Johns Hopkins Hosp* 1962;111:98–126.

Jang SY. Traumatic optic neuropathy. *Korean J Neurotrauma*. 2018;14(1):1-5.

Jeon CJ, Strettoi E, Masland RH. The major cell populations of the mouse retina. *J. Neurosci.*, November 1, 1998, 18(21):8936–8946.

Kaur C, Rathnasami G, Foulds WS, et al. Cellular and Molecular Mechanisms of Retinal Ganglion Cell Death in Hypoxic-Ischemic Injuries. *J Neurol Exp Neurosci.* 2015;1(1): 10-19.

Kim SH, Park JH, Kim YJ, et al. The neuroprotective effect of resveratrol on retinal ganglion cells after optic nerve transection. *Molecular vision* 2013;19:1667-76.

Kim WT, Suh ES. Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy. *Korean J. Ophthalmol.* 2010; 24: 108–18.

Kubota S, Kurihara T, ebinuma M, et al. Resveratrol Prevents Light Induced Retinal Regeneration via Suppressing Activator protein-1 Activation. *Am. J. Pathol.* 2010; 177: 1725-31.

Kubota S, Kurihara T, Mochimaru H, et al. Prevention of Ocular Inflammation in Endotoxin-induced Uveitis with Resveratrol by Inhibiting Oxidative Damage and Nuclear Factor Kappab activation. *Investig. Ophthalmol. Vis. Sci.* 2009; 50: 3512–19.

Kumaran AM, Sundar G, Lim TC. Traumatic Optic Neuropathy : A Review. *Craniomaxillofac Trauma Reconstruction* 2015; 8:31-41.

Kursvietiene L, Staneviciene I, Mongirdiene A, et al. Multiplicity of effect and a health benefit of resveratrol. *Medicina* 2016;52:148-155.

Lamkanfi M, Kanneganti TD. Caspase-7: A protease involved in apoptosis and inflammation. *The international journal of Biochemistry and cell biology.* 2010;42:21-24.

Larner SF, McKinsey DM, Hayes RL, et al. Caspase-7 Increased Expression and Activation After Traumatic Brain Injury in Rats. *J. Neurochem.* 2015; 94(1): 97-108.

Lee AG, Brazis PW. Traumatic Optic Neuropathy. In Clinical Pathways in Neuro-ophthalmology, An Evidence Based Approach. 2nd ed. New York: Thieme. 2003; 119-126.

Lee KF, Muhd Nor NI, Yaakub A, Wan Hitam, WH. Traumatic optic neuropathy: a review of 24 patients. *Int J Ophthalmol.* 2010;3(2):175-178.

Lee MK, Kang SJ, Ponchz M. resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. *Exp Mol Med* 2007;39(3):376-84.

Levin LA, Beck RW, Joseph MP, et al. (The International Optic Nerve Trauma Study Group). The treatment of traumatic optic neuropathy. The International Optic Nerve Trauma Study. *Ophthalmology.* 1999;106:168–1277.

Liang Y, Downs JC, Fortune B, et al. Systemic blood pressure on the relationship between intraocular pressure and blood flow in the optic nerve head of nonhuman primates. *Invest ophthal and vis sci.* 2009; 50(5):2154.

Lindsey JD, Duong-Polk KX, Hammond D, Leung CK, Weinreb RN. Protection of injured retinal ganglion cell dendrites and unfolded protein response resolution after long-term dietary resveratrol. *Neurobiology of Aging,* 2015(36); 1969-1981.

Liu XQ, Wu BJ, Pan WH, Zhang XM, Liu JH, Chen MM. Resveratrol mitigates rat retinal ischemic injury: The roles of matrix metalloproteinase-9, inducible nitric oxide, and heme oxygenase-1. *J.Ocul. Pharmacol.* 2013;29: 33-40.

Losso JN, Truax RE, Richard G, Trans-resveratrol Inhibits Hyperglycemia-induced Inflammation and Connexin Downregulation in Retinal Pigment Epithelial Cells. *J. Agric. Food Chem.* 2010;58: 8246-52.

Lulli M, Witort E, Papucci L, et al. Coenzyme Q10 instilled as eye drops on the cornea reaches the retina and protects retinal layers from apoptosis in a mouse model of kainate-induced retinal damage. *Invest Ophthalmol Vis Sci.* 2012;53(13):8295–302.

Luna C, Li G, Liton PB, et al. Resveratrol Prevents the Expression of Glaucoma Markers Induced by Chronic Oxidative Stress in Trabecular Meshwork Cells. *Food Chem Toxicol.* 2009; 47:198-204.

McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. *Invest Ophthalmol Vis Sci.* 2002;43:1077–87.

Naibaho H, Nusanti S, Sidik M. Karakteristik, Hasil terapi dan Prediktor Keberhasilan Terapi Pasien Neuropati Optik Traumatik Divisi Neurooftalmologi Rumah Sakit Ciptomangunkusumo. 2016.

Pervaiz S. Resveratrol: From Grapevines to Mammalian Biology. *FASEB J.* 2003; 17: 1975-85.

Pintea AM, Rugina DO. Resveratrol and the human retina. *Handbook of nutrition, diet and the eye.* 2014; 481-491.

Pirhan D, Yuksel N, Emre E, et al. Riluzole- and resveratrol-induced delay of retinal ganglion cell death in an experimental model of glaucoma. *Curr. Eye Res.* 2015;41:59-69.

Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for ampk activation and the beneficial effects of resveratrol on mitochondrial function. *Cell. Metab.* 2012, 15, 675-90.

Prihatningtias R, Wildan A, Yuliana C, Krisnugroho I. Comparisons of caspase-3 and caspase-7 expression from retinal ganglion cell apoptosis post folic acid and methylcobalamin administration in methanol toxic wistar rats model. *PJMHS* 12(3); 2019:1360-62.

Produit-Zengaffinen N, Pournaras CJ, Schorderet DF. Retinal ischemia-induced apoptosis is associated with alteration in Bax and Bcl-x(L) expression rather than modifications in Bak and Bcl-2. *Mol Vis*. 2009;15:2101–10.

Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. *Nat Rev Mol Cell Biol* 2002;3(6):401-10.

Sareen D, Van Ginkel PR, Takach JC, et al. Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. *Investig. Ophthalmol. Vis. Sci.* 2006; 47: 3708-16.

Sarkies N. Traumatic optic neuropathy. *Eye*. 2004;18:1122-5.

Shankar S, Nall D, Tang S, Meeker D, Passarini J, Sharma J, Srivastava RK. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and krasg12d transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. *PLoS ONE*, 2011; 6(1): e16530.

Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. *Nat Rev Mol Cell Biol*. 2010;11(9):621-32.

Teixeira VH, Jacq L, Lasbleiz S, et al. Genetic and expression analysis of CASP7 gene in a European Caucasian population with rheumatoid arthritis. *J Rheumatol* 2008;35:1912–8.

Thomas CN, Berry M, Logan A, Blanch RJ, Ahmed Z. Caspases in retinal ganglion cell death and axon regeneration. *Cell Death Discovery*. 2017.

Tse CB, Dvoriantchikova G, Tao W, et al. Tumor Necrosis Factor Inhibition in the Acute Management of Traumatic Optic Neuropathy. *Invest Ophthalmol Vis Sci*. 2018;59:2905– 2912.

Van Ginkel PR, Darjatmoko SR, Sareen D, et al. Resveratrol inhibits uveal melanoma tumor growth via early mitochondrial dysfunction. *Investig. Ophthalmol. Vis. Sci.* 2008; 49: 1299–1306.

Vanden Berghe T, Kersse K, Vandenabeele P. Caspase-3 and Caspase-7. *Handbook of Proteolytic Enzymes*. 2013; 2256–2265.

Xu X, Lai Y, Hua ZC. Apoptosis and Apoptotic Body : Disease Message and Therapeutic Target Potentials. *Bioscience Reports*. 2019; 39: 1-17.

Yaqoub M. Interpretation in Glaucoma: a focus on static automated perimetry. *Common eye health Journal*. 2012; 25: 1-8.

Yu-Wai-Man P. Traumatic Optic Neuropathy, Clinical Features and Management Issue. *Taiwan Journal of Ophthalmology*. 2015;5(1):3-8.

LAMPIRAN

1. Lembar persetujuan Komisi Etik



REKOMENDASI PERSETUJUAN ETIK

Nomor : 317/UN4.6.4.5.31/PP36/2020

Tanggal: 12 Juni 2020

Dengan Ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | |
|---|--|--|---------------------------|
| No Protokol | UH20040184 | No Sponsor Protokol | |
| Peneliti Utama | dr Yunita,Sp.M,M.Kes | Sponsor | |
| Judul Peneliti | Analisis Efek Resveratrol Terhadap Marker Apoptosis Caspase-7 dan Sel Ganglion Retina Pada Model Tikus Dengan Traumatic Optic Neuropathy | | |
| No Versi Protokol | 2 | Tanggal Versi | 8 April 2020 |
| No Versi PSP | 2 | Tanggal Versi | 8 April 2020 |
| Tempat Penelitian | laboratorium Hewan. Fak. Kedokteran Universitas Hasanuddin, Laboratorium Patologi Anatomi RSPTN Univ. Hasanuddin | | |
| Jenis Review | <input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard | Masa Berlaku 12 Juni 2020 Sampai 12 Juni 2021 | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian Kesehatan FK UH | Nama Prof.Dr.dr.Suryani As'ad.,MSc,Sp.GK (K) | Tanda tangan | Tanggal |
| Sekretaris Komisi Etik Penelitian Kesehatan FK UH | Nama dr. Agussalim Bukhari, M.Med, PhD, Sp.GK (K) | Tanda tangan | Tanggal |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

2. Master tabel penelitian

| No. | No. Sampel | Densitas sel ganglion retina | Ekspresi caspase 7 |
|-----|------------|------------------------------|--------------------|
| 1 | NR 1 | 25,7 | 8 |
| 2 | NL 1 | 15,4 | 12 |
| 3 | NR 2 | 22,8 | 3 |
| 4 | NL 2 | 22,45 | 22 |
| 5 | NR 3 | 20,92 | 8 |
| 6 | NL 3 | 25,9 | 16 |
| 7 | NR 4 | 24,54 | 7 |
| 8 | NL 4 | 17,72 | 5 |
| 9 | NR 5 | 27 | 10 |
| 10 | NL 5 | 27,8 | 3 |
| 11 | NR 6 | 29,81 | 13 |
| 12 | NL 6 | 29,84 | 7 |
| 13 | PR 1 | 0 | 0 |
| 14 | PL 1 | 25,78 | 16 |
| 15 | PR 2 | 22,5 | 0 |
| 16 | PL 2 | 17,5 | 4 |
| 17 | PR 3 | 25,75 | 2 |
| 18 | PL 3 | 23,45 | 14 |
| 19 | PR 4 | 15,25 | 2 |
| 20 | PL 4 | 32,41 | 12 |

| | | | |
|----|--------|-------|----|
| 21 | PR 5 | 27 | 10 |
| 22 | PL 5 | 25,8 | 4 |
| 23 | PR 6 | 24,3 | 16 |
| 24 | PL 6 | 26,83 | 5 |
| 25 | RR 1 A | 29,4 | 7 |
| 26 | RL 1 A | 26,87 | 4 |
| 27 | RR 2 A | 27,4 | 5 |
| 28 | RL 2 A | 20,12 | 4 |
| 29 | RR 3 A | 30,11 | 3 |
| 30 | RL 3 A | 0 | 0 |
| 31 | RR 4 A | 11,25 | 7 |
| 32 | RL 4 A | 24,09 | 14 |
| 33 | RR 5 A | 23,25 | 6 |
| 34 | RL 5 A | 19,36 | 6 |
| 35 | RR 6 A | 26 | 9 |
| 36 | RL 6 A | 19,57 | 20 |
| 37 | RR 1 B | 22,28 | 3 |
| 38 | RL 1 B | 24,53 | 8 |
| 39 | RR 2 B | 21,67 | 2 |
| 40 | RL 2 B | 26,84 | 1 |
| 41 | RR 3 B | 0 | 0 |
| 42 | RL 3 B | 22,54 | 7 |
| 43 | RR 4 B | 20,3 | 3 |
| 44 | RL 4 B | 24 | 7 |

| | | | |
|----|--------|-------|----|
| 45 | RR 5 B | 25,46 | 5 |
| 46 | RL 5 B | 30,8 | 33 |
| 47 | RR 6 B | 34,76 | 7 |
| 48 | RL 6 B | 22,3 | 4 |

| | |
|---------------|---|
| N | Normal (tanpa perlakuan Trauma) |
| P | Placebo (perlakuan Trauma, tanpa pemberian obat) |
| R--A | Resveratrol (perlakuakn trauma, dengan pemberian obat 10 mg/kgBB) |
| R--B | Resveratrol (perlakuakn trauma, dengan pemberian obat 20 mg/kgBB) |
| R (huruf ke2) | mata kanan |
| L (huruf ke2) | mata kiri |

**Perlakuan trauma hanya dilakukan pada mata KANAN,
Mata KIRI tidak dilakukan trauma (bisa berlaku kontrol
pada tikus yg sama)**

| | | |
|----------|--------|--|
| contoh : | NR 1 | mata kanan tikus Normal; tanpa dilakukan trauma maupun diberi obat mata kanan tikus |
| | PR 2 | Plasebo; dilakukan trauma tanpa diberi obat mata kanan tikus |
| | RR 1 A | Resveratrol; dilakukan trauma dan diberi obat 10 mg/KgBB mata kiri tikus |
| | RL 1 A | Resveratrol; TIDAK dilakukan trauma dan diberi obat 10 mg/KgBB |

| | |
|--------|--|
| RR 2 B | mata kanan tikus Resveratrol; dilakukan trauma dan diberi obat 20 mg/KgBB mata kiri tikus |
| RL 2 B | Resveratrol; TIDAK dilakukan trauma dan diberi obat 20 mg/KgBB |

3. Daftar riwayat hidup penulis

A. Data pribadi

Nama : Yunita
Tempat dan tanggal lahir : Ujung Pandang, 14 Juni 1981
Agama : Islam
Orang tua : Drs. Mansyur Toba
Ratna Sila
Suami : Jirana Sarifuddin, ST
Anak : Einarsufi Khumairah
Alamat : Citra Garden Blok I1 No. 1.
Sungguminasa, Gowa

B. Riwayat pendidikan

1. Tahun 2006 : Dokter umum FK Univ. Hasanuddin
2. Tahun 2010 : Spesialis Mata FK Univ. Hasanuddin
3. Tahun 2011 : Fellowship Neurooftalmologi RS. Cicendo
Bandung
4. Tahun 2013 : Fellowship Neurooftalmologi Queen Elizabeth
Hospital, Birmingham, United Kingdom
5. Tahun 2014 : Training Neurooftalmologi oleh ORBIS Flying
Eye hospital, Makassar

C. Riwayat pekerjaan

- a. Dokter spesialis mata RS Wahidin Sudirohusodo Makassar tahun 2012 - sekarang
- b. Dosen luar biasa Departemen Ilmu Kesehatan Mata FK Unhas tahun 2015 – sekarang

4. Dokumentasi saat melakukan penelitian

